TA911 · STA

Selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancer

June 2023

Source documents

Final Appraisal Document Committee Papers Scope Scope Consultation Comments

Intervention

selpercatinib

Condition

ret fusion-positive advanced non-small-cell lung canceroncology · advanced

Special considerations

Equality issues raised